Article Sidebar

PDF
Date Published: 17/06/2022
Abstract Views: 377
Views PDF: 224
DOI: https://doi.org/10.51298/vmj.v513i2.2478
Issue
Vol. 513 No. 2 (2022)
Section
Các bài báo
How to Cite
Thị Thu Trang, P. ., Thanh Đức, L. ., & Thị Thanh Bình, H. . (2022). RESULTS OF TREATMENT IN ENDOMETRIAL CANCER STAGE III IN NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 513(2). https://doi.org/10.51298/vmj.v513i2.2478

RESULTS OF TREATMENT IN ENDOMETRIAL CANCER STAGE III IN NATIONAL CANCER HOSPITAL

Phạm Thị Thu Trang1,, Lê Thanh Đức1, Hàn Thị Thanh Bình1
1 K Hospital

Main Article Content

Abstract

Objectives: Clinical, paraclinical systoms of endometrial cancer (EC) stage III. DFS (Disease free survival) of EC stage III after treatment. Patients and methods: 60 patients with EC stage III in National cancer Hospital from January 2016 to December 2020, who were treated by surgery, radiotherapy and chemotherapy, observing them to their recurrence. Results: median age was 56. The most common clinical system is abnormal vaginal bleeding. The rate of high CA12.5 level was 60%. Endometriod carcinoma was the most common pathology with 73,34%. ER positive rate was 59,52%, PR positive rate was 54,76%. Median DFS was 30,86±4,20 months.EC stage IIIA/B patients had DFS longer than stage IIIC patients. ER/PR positive was a good prognosis factor. High CA12.5 level was a poor prognosis factor. Conclusion: The endometrial cancer patients after treatment had DFS with 30,86 months.

Article Details

Keywords

endometrial cancer stage III, desease free survival

References

1. https://seer.cancer.gov/statfacts/html/corp.html.
2. Trần Văn Thuấn. Ung Thư Học Đại Cương.
3. Vũ Đình Giáp. Nhận xét kết quả điều trị ung thư nội mạc tử cung giai đoạn III, IV tại bệnh viện K. Luận văn thạc sỹ y học chuyên ngành ung thư, Trường Đại học Y hà Nội. Published online 2016.
4. H. Hricak, L. V. Rubinstein, G. M. Gherman, et al (1991). MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study. Radiology, 179 (3), 829-832.
5. J M Duk etal, “ CA 125: a useful marker in endometrial carcinoma”. Am J Obstet Gynecol 2016 Nov15551097-102 Doi 1010160002-93788690358-3.
6. Lê Văn Phúc (2011). Nghiên cứu đặc điểm mô bệnh học và tỷ lệ bộc lộ các thụ thể ER, PR trong ung thư biểu mô nội mạc tử cung, Luận văn thạc sỹ Y học, chuyên ngành Giải phẫu bệnh, Trường Đại học Y Hà Nội
7. Caifeng Wang et al, “ Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer”, J Cancer. 2020 Jan 16;11(7):1693-1701
8. Ulas Solmaz. Lymphovascular space invasion and positive pelvic lymph nodes are independent risk factors for para-aortic nodal metastasis in endometrioid endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2015 Mar18663-7 Doi 101016jejogrb201501006 Epub 2015 Jan 23.
9. Outcomes of patients with surgically and pathologically staged IIIA-IVB pure endometrioid-type endometrial cancer: a Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article). April 2016Medicine 9515e3330 DOI101097MD 0000000000003330. Published online 2016.